Orchestra BioMed is a pioneering biomedical innovation company that is dedicated to developing innovative therapeutic products to address crucial unmet clinical needs in procedure-based medicine. With a special focus on accelerating high-impact technologies, Orchestra BioMed collaborates with leading medical device companies to bring these transformative products to patients. Their partnership-enabled business model is centered around strategic collaborations, ensuring successful global commercialization of their developed products.

Led by a highly accomplished management team and board of directors with extensive experience in therapeutic device development, Orchestra BioMed is committed to making a significant impact in the field. Their pipeline consists of cutting-edge therapeutic product candidates that hold immense potential for value creation. Notably, they have two flagship technologies in late-stage development – BackBeat Cardiac Neuromodulation Therapy™ (CNT™) and Virtue® Sirolimus AngioInfusion™ Balloon (SAB).

BackBeat CNT™ is a patented bioelectronic treatment designed to deliver a substantial reduction in blood pressure while simultaneously modulating the autonomic nervous system response. Virtue® SAB, on the other hand, is a drug/device combination product candidate designed to deliver a proprietary formulation of sirolimus during balloon angioplasty without the need for a permanent implant or balloon coating. Please note that Virtue® SAB and BackBeat CNT™ are not yet approved for commercial use in the US